Tech Company Financing Transactions
ImmunoScape Funding Round
ImmunoScape, based in Singapore, secured $14 million in funding from Anzu Partners, Amgen Ventures and Edbi.
Transaction Overview
Company Name
Announced On
9/20/2022
Transaction Type
Venture Equity
Amount
$14,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The new funding will allow us to expedite our development efforts and help us to advance our therapeutic candidates toward the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Scotts Rd. 24-10
Singapore, 228208
Singapore
Singapore, 228208
Singapore
Phone
Undisclosed
Website
Email Address
Overview
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. Our proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple solid tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Choon-Peng Ng
Chief Financial Officer
Romi Chandiramani
Chief Operating Officer
Alessandra Nardin
Vice President
Mathew Cobbett
Vice President
Dan MacLeod
VP - Operations
Michael Fehlings
Browse more venture capital transactions:
Prev: 9/20/2022: Rentle venture capital transaction
Next: 9/20/2022: Sequence venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs